Osang Healthcares COVID-19 and...
페이지 정보
본문
The approved combo kit is a diagnostic device that can distinguish COVID-19 and influenza A and B at the same time. In particular, steady demand is expected in the United States. This is because the number of patients with respiratory infections in the United States is increasing every year. The Centers for Disease Control and Prevention CDC estimates that more than 110,000 people have been hospitalized and 6,500 have died from the flu this winter alone. Osang Healthcare already has a number of FDA approved references. In 2003, a personal glucose meter was officially approved, and in 2020, the COVID-19 molecular diagnostic kit was delivered to the U.S. federal government after emergency use approval. 관련기사 ▶ SPC Paris Baguette enters Italy ▶ The Fair Trade Commission sanctions four companies that colluded for 17 years in bids ordered by KEPCO. ▶ A bullet was found inside the Korean Air aircraft and related agencies launched an investigation. ▶ LS Group abolishes RSUs just one year after introduction ▶ Lim Joo-hyun, CEO of Hanmi Pharmaceutical, If integrated with OCI, we will not dispose of stocks for three years. / 알파경제 Kim Jisun Reporter |
관련링크
- 이전글[속보]한미그룹, 임종윤·임종훈 한미약품 사장 해임 24.03.25
- 다음글실적 꺾인 1위 이마트, 창사 이래 첫 희망퇴직 받는다 24.03.25
댓글목록
등록된 댓글이 없습니다.